Although no checkpoint inhibitors are currently FDA-approved in this space, there is a strong rationale for combining HER2-targeted therapies with ICI to increase efficacy in breast cancer, particularly in the early-stage setting, where the immune system has not been weakened by heavy pretreatment. This evidence concerns the gene ERBB2 and breast carcinoma.